GO:1902003 regulation of amyloid-beta formation: Mechanism, Genes, Functions and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:1902003 (regulation of amyloid-beta formation) is a biological process that modulates the frequency, rate, or extent of amyloid-beta (Aβ) production.
• Aβ is generated by sequential cleavage of amyloid precursor protein (APP) by β-secretase (BACE1) and γ-secretase (presenilin complex).
• Key regulators include APP phosphorylation, protein interactions, lipid metabolism, and endolysosomal trafficking.
• Dysregulation of Aβ formation is central to Alzheimer's disease pathogenesis, with APOE and presenilin mutations as major risk factors.
• Therapeutic strategies targeting Aβ formation include anti-amyloid antibodies like donanemab, recently approved for Alzheimer's disease.
• CRISPR-based models (knockout, point mutation, knock-in, overexpression) enable causal dissection of genes regulating Aβ formation.
Description
GO:1902003, regulation of amyloid-beta formation, is a biological process that encompasses any mechanism modulating the production of amyloid-beta (Aβ) peptides. Aβ peptides are derived from the amyloid precursor protein (APP) through proteolytic processing, and their accumulation is a hallmark of Alzheimer's disease (AD). Understanding how Aβ formation is regulated is critical for developing therapeutic interventions that target early steps in AD pathogenesis. This article synthesizes authoritative QuickGO annotations and published literature to provide a comprehensive overview of the molecular players, regulatory mechanisms, and experimental models relevant to GO:1902003.
regulation of amyloid-beta formation At A Glance
| GO ID | GO:1902003 |
|---|---|
| GO term | regulation of amyloid-beta formation |
| Ontology | biological_process |
| Synonym | regulation of beta-amyloid formation |
| Definition | Any process that modulates the frequency, rate or extent of amyloid-beta formation. |
| Major function | Modulation of Aβ peptide production from APP |
| Related processes | APP processing, endolysosomal trafficking, lipid metabolism |
| Key enzymes | BACE1, γ-secretase complex (PSEN1/PSEN2) |
| Disease relevance | Alzheimer's disease, cerebral amyloid angiopathy |
What Is GO:1902003?
According to the Gene Ontology, GO:1902003 (regulation of amyloid-beta formation) is defined as any process that modulates the frequency, rate, or extent of amyloid-beta formation. This includes both positive and negative regulation of the proteolytic cleavage events that generate Aβ peptides from APP, as well as processes affecting the availability or activity of the enzymes involved.
Why Is regulation of amyloid-beta formation Important in Cell Biology?
Regulation of amyloid-beta formation is critically important because Aβ accumulation is an early and central event in Alzheimer's disease pathogenesis. Genetic mutations in APP, PSEN1, and PSEN2 that increase Aβ production cause early-onset familial AD, while APOE ε4 is the strongest genetic risk factor for late-onset AD. Moreover, therapeutic strategies aimed at reducing Aβ formation, such as β-secretase inhibitors and anti-amyloid antibodies, are actively being developed and tested. Thus, understanding the regulatory mechanisms of Aβ formation is essential for identifying new drug targets and biomarkers.
• Aβ is a key pathogenic peptide in Alzheimer's disease.
• Mutations in APP and presenilins alter Aβ formation and cause familial AD.
• APOE isoforms differentially regulate Aβ aggregation and clearance.
• Lipid metabolism, including cholesterol and sphingomyelin, modulates Aβ production.
• Endolysosomal trafficking and Aurora Kinase A influence Aβ levels in neurons.
• Microglial phagocytosis of Aβ is regulated by SELENOK-dependent CD36 palmitoylation.
• Therapeutic antibodies like donanemab target Aβ and have been approved for AD.
• Regulation of Aβ formation is a major focus for drug discovery and biomarker development.
What Happens During regulation of amyloid-beta formation?
APP processing and Aβ generation
In simple terms: Amyloid-beta is cut out of a larger protein called APP by two enzymes, like scissors cutting a string.
Amyloid-beta (Aβ) is produced through sequential cleavage of amyloid precursor protein (APP) by β-secretase (BACE1) and γ-secretase complex. The γ-secretase complex contains presenilin (PSEN1 or PSEN2) as the catalytic subunit. Regulation of this process can occur at multiple levels, including APP expression, trafficking, and enzyme activity.
Regulation by phosphorylation and protein interactions
In simple terms: Adding phosphate groups to APP or other proteins can change how APP is processed.
Phosphorylation of APP and its interacting proteins regulates APP trafficking and cleavage, thereby modulating Aβ formation. For example, phosphorylation of APP at specific residues can influence its localization to lipid rafts or endosomes, where β- and γ-secretases are enriched.
Lipid metabolism and membrane composition
In simple terms: Fats in the cell membrane can affect how the enzymes that make amyloid-beta work.
Cholesterol and sphingomyelin metabolism regulate Aβ production and presenilin activity. Aβ itself can act as a regulator of lipid homeostasis, creating a feedback loop that influences its own formation. These findings highlight the interplay between lipid metabolism and Aβ generation.
Endolysosomal trafficking and degradation
In simple terms: The cell's recycling system can control how much amyloid-beta is made or broken down.
Endolysosomal pathways are involved in the regulation of Aβ levels in neurons. Aurora Kinase A has been implicated in modulating Aβ production through effects on endolysosomal trafficking. Disruption of these pathways can lead to altered Aβ formation and accumulation.
Microglial clearance and immune regulation
In simple terms: Immune cells in the brain can eat up amyloid-beta, and this process is regulated by specific proteins.
Microglial phagocytosis of Aβ is regulated by SELENOK-dependent CD36 palmitoylation. This indicates that immune cells contribute to the regulation of Aβ levels, and their dysfunction may exacerbate Aβ accumulation.
Key Genes Involved in GO:1902003 regulation of amyloid-beta formation
The following genes and proteins are key players in the regulation of amyloid-beta formation, as supported by published literature.
| Gene | Major Role | Research Relevance |
|---|---|---|
| APP | Amyloid precursor protein; substrate for Aβ generation | Mutations cause familial AD; central to Aβ formation |
| BACE1 | β-secretase; cleaves APP to generate Aβ | Therapeutic target; knockout reduces Aβ |
| PSEN1 | Catalytic subunit of γ-secretase | Mutations cause early-onset AD; regulates Aβ production |
| PSEN2 | Subunit of γ-secretase | Mutations linked to familial AD |
| APOE | Lipid transport; modulates Aβ aggregation and clearance | ε4 allele is strongest risk factor for late-onset AD |
| AURKA | Aurora Kinase A; regulates endolysosomal trafficking | Influences Aβ levels in neurons |
| SELENOK | Selenoprotein K; regulates CD36 palmitoylation | Modulates microglial Aβ phagocytosis |
| CD36 | Scavenger receptor; mediates microglial Aβ uptake | Palmitoylation by SELENOK affects function |
| RAGE | Receptor for advanced glycation endproducts | Mediates oxidative stress and inflammation; linked to Aβ |
| NOX4 | NADPH oxidase 4; produces reactive oxygen species | Involved in RAGE-mediated oxidative stress |
| Dioscin | Natural compound; modulates RAGE/NOX4 pathway | Alleviates AD in models |
| Cholesterol | Membrane lipid; regulates APP processing | Metabolism linked to Aβ production |
| Sphingomyelin | Membrane lipid; affects presenilin activity | Regulates Aβ formation |
| Aβ | Amyloid-beta peptide; product of APP cleavage | Central to AD pathogenesis |
How Is regulation of amyloid-beta formation Regulated?
The regulation of amyloid-beta formation is a complex process influenced by multiple pathways. APP phosphorylation and protein interactions directly modulate its cleavage by secretases. Lipid metabolism, including cholesterol and sphingomyelin, affects the membrane environment where APP processing occurs. Endolysosomal trafficking determines the localization of APP and secretases, thereby impacting Aβ production. Additionally, microglial phagocytosis regulated by SELENOK and CD36 contributes to Aβ clearance, indirectly affecting overall Aβ levels. These regulatory layers provide multiple points for therapeutic intervention.
regulation of amyloid-beta formation and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| APP | Alzheimer's disease | Knock-in of familial mutations (e.g., Swedish, London) in cell lines |
| PSEN1 | Early-onset Alzheimer's disease | Knockout or point mutation in iPSCs followed by neuronal differentiation |
| APOE | Late-onset Alzheimer's disease | Knock-in of ε4 allele in isogenic iPSCs or mice |
| BACE1 | Alzheimer's disease (therapeutic target) | Knockout in neurons to assess Aβ reduction |
| AURKA | Aβ regulation in neurons | Overexpression or knockout in neuroblastoma cells |
Alzheimer's disease
Alzheimer's disease (AD) is the most common neurodegenerative disorder, characterized by Aβ plaques and neurofibrillary tangles. Dysregulation of Aβ formation, leading to increased production or reduced clearance, is a central event in AD pathogenesis. Mutations in APP, PSEN1, and PSEN2 cause early-onset familial AD by increasing Aβ production. The APOE ε4 allele is the strongest genetic risk factor for late-onset AD and influences Aβ aggregation and clearance. Therapeutic approaches targeting Aβ, such as the anti-amyloid antibody donanemab, have shown clinical benefit.
Cerebral amyloid angiopathy
Cerebral amyloid angiopathy (CAA) is characterized by Aβ deposition in cerebral blood vessels, leading to vascular fragility and hemorrhagic stroke. Dysregulation of Aβ formation and clearance contributes to CAA pathogenesis, often coexisting with AD.
Neuroinflammation
Aβ accumulation triggers neuroinflammatory responses, including microglial activation and release of proinflammatory cytokines. SELENOK-dependent CD36 palmitoylation regulates microglial phagocytosis of Aβ, and its dysfunction may exacerbate inflammation. RAGE/NOX4 signaling mediates oxidative stress and inflammation in AD models.
From regulation of amyloid-beta formation-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| Does gene X regulate Aβ formation? | CRISPR knockout in APP-expressing cell lines (e.g., HEK293, SH-SY5Y) |
| Does a specific mutation affect Aβ production? | Point mutation knock-in using CRISPR in iPSCs or cell lines |
| Does a risk variant alter APP processing? | Knock-in of variant allele in isogenic cell lines |
| Where does a protein of interest localize? | Tagged knock-in (e.g., GFP) for imaging |
| Does overexpression of gene Y increase Aβ? | CRISPR activation or lentiviral overexpression |
| Can a drug modulate Aβ formation? | Pharmacological screening in knockout or reporter cell lines |
How to Study the regulation of amyloid-beta formation Process
| Method | What It Measures | Typical Application |
|---|---|---|
| ELISA | Aβ40/Aβ42 concentrations | Quantify Aβ in conditioned media |
| Western blot | APP and cleavage products | Assess APP processing |
| CRISPR screen | Gene knockouts affecting Aβ | Identify novel regulators |
| Immunofluorescence | Protein localization | Study APP trafficking |
| Lipidomics | Cholesterol/sphingomyelin levels | Link lipid metabolism to Aβ |
| RNA-seq | Transcriptional changes | Global effects of perturbations |
| Proteomics | Protein interactions | Identify APP interactors |
CRISPR knockout screening
Genome-wide CRISPR knockout screens can identify genes that regulate Aβ formation. Cells expressing APP and a reporter for Aβ (e.g., luciferase) are transduced with a sgRNA library, and sgRNAs that alter Aβ levels are enriched and sequenced.
Biochemical assays for Aβ
Aβ levels can be measured by ELISA, Western blot, or mass spectrometry in conditioned media or cell lysates. These assays are used to validate hits from screens and to assess the effects of genetic perturbations.
Imaging and trafficking studies
Fluorescence microscopy and live-cell imaging can track APP trafficking and co-localization with secretases. Tagged knock-in models (e.g., APP-GFP) allow visualization of APP processing in real time.
Lipidomics and metabolomics
Mass spectrometry-based lipidomics can quantify cholesterol and sphingomyelin levels, which are known to regulate Aβ formation.
How CRISPR Can Be Used to Study GO:1902003 regulation of amyloid-beta formation
Knockout
CRISPR knockout of candidate genes (e.g., BACE1, PSEN1) in APP-expressing cells can determine whether they are required for Aβ formation. Knockout of BACE1 reduces Aβ production, validating its role.
Point Mutation
Introducing familial AD mutations (e.g., APP Swedish, PSEN1 M146V) using CRISPR point mutation allows study of their effects on Aβ formation in isogenic backgrounds.
Knock-in
Knock-in of risk variants (e.g., APOE ε4) or tagged endogenous genes (e.g., APP-GFP) enables precise modeling of disease-associated alleles and visualization of protein dynamics.
Overexpression
CRISPR activation (CRISPRa) or lentiviral overexpression can increase gene expression to test whether a gene is sufficient to drive Aβ formation. Overexpression of APP or BACE1 increases Aβ levels.
How EDITGENE Supports regulation of amyloid-beta formation Research
Researchers studying regulation of amyloid-beta formation-related genes often need to determine whether a candidate gene is causally involved in Aβ production or clearance. EDITGENE provides a comprehensive suite of CRISPR-based services to enable such investigations, from knockout to knock-in and overexpression models, as well as high-throughput screening and bioinformatics support.
Contact EDITGENE today to design your custom CRISPR model for regulation of amyloid-beta formation research.
Frequently Asked Questions About regulation of amyloid-beta formation
What is GO:1902003?
GO:1902003 is the Gene Ontology term for regulation of amyloid-beta formation, defined as any process that modulates the frequency, rate or extent of amyloid-beta formation.
What genes are involved in regulation of amyloid-beta formation?
Key genes include APP, BACE1, PSEN1, PSEN2, APOE, AURKA, SELENOK, and CD36.
How is amyloid-beta formed?
Amyloid-beta is generated by sequential cleavage of APP by β-secretase (BACE1) and γ-secretase (presenilin complex).
What diseases are associated with dysregulation of amyloid-beta formation?
Alzheimer's disease and cerebral amyloid angiopathy are the primary diseases linked to dysregulated Aβ formation.
What is the role of APOE in amyloid-beta formation?
APOE modulates Aβ aggregation and clearance, with the ε4 allele increasing risk for late-onset Alzheimer's disease.
How can CRISPR be used to study regulation of amyloid-beta formation?
CRISPR knockout, point mutation, knock-in, and overexpression can be used to test the causal role of specific genes in Aβ production.
What are the main regulatory mechanisms of amyloid-beta formation?
Regulation occurs at multiple levels, including APP phosphorylation, protein interactions, lipid metabolism, and endolysosomal trafficking.
What is the role of microglia in amyloid-beta regulation?
Microglia phagocytose Aβ, and this process is regulated by SELENOK-dependent CD36 palmitoylation.
What therapeutic strategies target amyloid-beta formation?
β-secretase inhibitors and anti-amyloid antibodies like donanemab are being developed to reduce Aβ formation.
How is amyloid-beta measured in research?
Aβ levels are commonly measured by ELISA, Western blot, or mass spectrometry in conditioned media or cell lysates.
Conclusion
GO:1902003 (regulation of amyloid-beta formation) is a critical biological process with profound implications for Alzheimer's disease and related disorders. The interplay of APP processing, lipid metabolism, endolysosomal trafficking, and immune regulation determines Aβ levels. CRISPR-based models offer powerful tools to dissect these mechanisms and identify therapeutic targets. Continued research into the regulation of Aβ formation will be essential for developing effective treatments for AD.
References
- 1. Liu CC et al.. 2013. Apolipoprotein E and Alzheimer disease: risk, mechanisms and therapy.. Nat Rev Neurol 9(2):106-18 PMID: 23296339
- 2. Kang C. 2024. Donanemab: First Approval.. Drugs 84(10):1313-1318 PMID: 39237715
- 3. Ouyang P et al.. 2024. SELENOK-dependent CD36 palmitoylation regulates microglial functions and Aβ phagocytosis.. Redox Biol 70:103064 PMID: 38320455
- 4. Suzuki T et al.. 2008. Regulation of amyloid beta-protein precursor by phosphorylation and protein interactions.. J Biol Chem 283(44):29633-7 PMID: 18650433
- 5. Guan L et al.. 2022. Dioscin alleviates Alzheimer's disease through regulating RAGE/NOX4 mediated oxidative stress and inflammation.. Biomed Pharmacother 152:113248 PMID: 35691153
- 6. Afghah Z et al.. 2024. Involvement of Endolysosomes and Aurora Kinase A in the Regulation of Amyloid β Protein Levels in Neurons.. Int J Mol Sci 25(11) PMID: 38892390
- 7. Grimm MO et al.. 2005. Regulation of cholesterol and sphingomyelin metabolism by amyloid-beta and presenilin.. Nat Cell Biol 7(11):1118-23 PMID: 16227967
- 8. Grimm MO et al.. 2007. Amyloid beta as a regulator of lipid homeostasis.. Trends Mol Med 13(8):337-44 PMID: 17644432
